GRAIL Completes Final Study Visits for the NHS-Galleri Trial; Final Results Expected in 2026 PATHFINDER 2 is a prospective, multi-center, interventional study evaluating the safety and performance of ...
GRAIL's topline results from the NHS-Galleri trial were a clear disappointment with no major implications on commercialization. Read why GRAL stock is a hold.
GRAIL Completes Enrollment of More Than 35,000 Participants in the PATHFINDER 2 Study; Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results